ArticleGene therapy2018
Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters.
Article in Gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Gold Nanoparticles-Enhanced Gene Transfer Driven by MHz-Frequency Nanosecond Pulsed Electric Fields.Biomolecules · 2025Article
- RecombinantFuture microbiology · 2025Article
- Electroporation in Cancer Therapy: A Simplified Model Derived from the Hodgkin-Huxley Model.Bioelectricity · 2024Article
- Gene Immunotherapy of Colon Carcinoma with IL-2 and IL-12 Using Gene Electrotransfer.International journal of molecular sciences · 2023Article
- Antitumor Activities of Interleukin-12 in Melanoma.Cancers · 2022Review
- Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response.Cancer gene therapy · 2022Article
- Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.Molecular therapy oncolytics · 2022Article
- Viruses as tools in gene therapy, vaccine development, and cancer treatment.Archives of virology · 2022Review
- Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.Nature biomedical engineering · 2022Article
- Intratumoral Plasmid IL12 Expands CD8Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Article
- Furin-responsive triterpenine-based liposomal complex enhances anticervical cancer therapy through size modulation.Drug delivery · 2020Article
- The Efficiency of Gene Electrotransfer in Breast-Cancer Cell Lines Cultured on a Novel Collagen-Free 3D Scaffold.Cancers · 2020Article
- Localized Interleukin-12 for Cancer Immunotherapy.Frontiers in immunology · 2020Review
- Production and Application of Multicistronic Constructs for Various Human Disease Therapies.Pharmaceutics · 2019Review
- A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer.International journal of molecular sciences · 2019Article
- Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.Cancer gene therapy · 2019Article
- Local Delivery ofCancer research · 2019Article
- Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.Gene therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of immunomodulatory cytokines has been shown effective in regressing a wide range of tumors. However, systemic delivery of recombinant cytokines results in serious, potentially life-threatening, adverse effects. By contrast, nucleic acid transfer via electroporation (EP) is a safe and effective method of delivering plasmid-encoded cytokines to tumors. Intratumoral delivery of IL-12 plasmid DNA by electroporation (IT-pIL12-EP) produced objective response rates in Phase 2 clinical trials in metastatic melanoma. However, only 17.9% of patients receiving IT-pIL12-EP show a complete therapeutic response. Here, we sought to improve the antitumor efficacy of our clinical IT-pIL12-EP plasmid electroporation platform. We evaluated multiple plasmid designs for IL-12 expression. IL-12 expression from a plasmid incorporating a picornavirus-derived co-translational P2A site was the most effective in expressing IL-12p70. In addition, modifying the electroporation parameters improved transfection efficiency and expression of plasmid-derived IL-12p70, as well as its downstream effector IFN-γ in vivo. Finally, using a murine melanoma model that is representative of the intended target patient population, we show that combining modified electroporation conditions with the pIL12-P2A plasmid expression enhances the systemic antitumor response. These improvements to the IT-pIL12-EP platform may improve patient clinical response rates and survival when translated to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.